Treatment for High Blood Pressure (Hypertension)

Phase-Based Progress Estimates
Highland Family Medicine, Rochester, NY
High Blood Pressure (Hypertension)+1 More
All Sexes
What conditions do you have?

Study Summary

The overall goal of this study is to identify and rigorously evaluate strategies for implementing and sustaining team-based home blood pressure monitoring (TB-HBPM) within primary care. The TB-HBPM intervention is a multifaceted program involving patient transmission of blood readings to EHR and clinical decision support. Implementation strategies include group-based education on hypertension measurement, target blood pressure goals, drug and lifestyle management, referral to community resources, and team training designed to optimize the coordination of hypertension care, and monthly audit and feedback reports to teams and clinicians. Hypertension control rates are suboptimal in many primary care practices with persistent racial disparities in control. Team-based home blood pressure monitoring (TB-HPBM) involving patient transmission of their home blood pressure readings in real-time to their clinical team has been shown to improve blood pressure control. There is an urgent need to implement TB-HBPM into practice. The overall objective of this research is to assess implementation strategies that mitigate barriers and leverage facilitators to TB-HBHM on hypertension control and disparities between Black and White patients. The study team and investigators will use mixed methods to assess the process and generate knowledge to facilitate broader uptake of TB-HBPM.

Eligible Conditions

  • High Blood Pressure (Hypertension)

Treatment Effectiveness

Study Objectives

1 Primary · 7 Secondary · Reporting Duration: Beginning with the 6-month intervention period and up to 48 months participation

Month 48
Participation in Home Blood Pressure Monitoring (HBPM)
Month 48
Sustained blood pressure control
First three months following each participant's enrollment in HBPM
Transmission of home blood pressure readings
Pre-intervention and six months post-intervention
Chronic disease self-management capacity (QICA)
Month 48
Anti-hypertensive medication intensification
Blood pressure control
Blood pressure control by insurance
Blood pressure control by race and ethnicity
Clinician mean blood pressure (BP) goal (mm Hg) for patients
Cost Analysis
Exploratory outcomes- Hypertension-related Emergency department visits
Exploratory outcomes- Hypertension-related Hospitalizations
Exploratory outcomes- LDL control levels
Exploratory outcomes- Smoking status
Team function
The percentage of participants who are managed by a clinical pharmacist

Trial Safety

Trial Design

0 Treatment Group

5760 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: beginning with the 6-month intervention period and up to 48 months participation

Trial Background

Prof. Kevin Fiscella, Professor, Family Medicine
Principal Investigator
University of Rochester
Closest Location: Highland Family Medicine · Rochester, NY
Photo of Rochester  1Photo of Rochester  2Photo of Rochester  3
2014First Recorded Clinical Trial
1 TrialsResearching High Blood Pressure (Hypertension)
2 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are an HFM employee (practice leaders, administrators, clinicians, or staff) that works with hypertensive patients during the study period.
You have a diagnosis of hypertension.
You have a diagnosis of hypertension based on ICD-10 codes of I10-I14.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.